Seventy-eight percent alive and free of chronic graft-versus-host disease at one year. The control arm — a standard transplant — hit 38 percent. The hazard ratio was 0.26. That is not a gradient. That is a break.
The Phase 3 Precision-T trial showed 78% cGVHD-free survival at 12 months vs 38% with conventional transplant — a 74% improvement in the primary endpoint.
The company raised over $600 million to build a single-cell precision manufacturing platform that reformulates donor stem cell grafts. It now faces the commercial test: converting clinical data into a standard-of-care procedure at ~25 transplant centers by year-end.
Tregzi Phase 3 Precision-T primary endpoint
Chronic graft-versus-host-disease-free survival at 12 months: 78% vs 38% (unmanipulated allograft). Hazard ratio 0.26 (p < 0.00001). Moderate-to-severe cGVHD: 12.6% vs 44.0% (HR 0.19). Overall survival at one year: 94% vs 83%. · FDA prescribing information, June 2026
The numbers from the Precision-T trial resolve a tension that has defined allogeneic stem cell transplant for decades. The graft-versus-leukemia effect is real — donor immune cells kill residual cancer cells — but the same cells attack the patient's healthy tissue. Chronic GVHD can scar the skin, dry the eyes, stiffen the joints, and narrow the lungs. It is the reason many transplant survivors trade their disease for a different kind of chronic illness.
The therapy works by separating the two signals. It delivers three cell populations from a matched donor in sequence: hematopoietic stem cells for reconstitution, purified regulatory T cells to suppress GVHD, and conventional T cells to drive the anti-leukemia effect. The Tregs arrive first and establish an immune barrier before the conventional T cells enter. The data suggest the barrier holds.
For transplant physicians, one of our greatest challenges has long been preserving the vital graft-versus-leukemia effect while minimizing the risk of GVHD and infection. The FDA approval of Tregzi signals a new era in transplant medicine.— Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center
How the therapy re-engineers the graft
A standard stem cell transplant infuses a mixed bag of stem and immune cells from a matched healthy donor directly into the patient. The composition varies by donor. The product replaces that lottery with a defined composition.
The company's manufacturing platform sorts donor cells at single-cell precision, isolating CD34+ stem cells, CD4+ regulatory T cells, and conventional T cells into three separate bags. Each component is dosed by patient weight. The Tregs are infused on day 0 alongside the stem cells; the conventional T cells follow on day 2 or 3. The delay gives the Tregs time to migrate to the organs and establish tolerance before the tumor-killing cells arrive.
The therapy vs conventional allogeneic HSCT — key differences
Graft composition: The therapy uses purified, defined cell populations (HSPCs + Tregs + Tcons). Conventional allograft uses unmanipulated donor cells with variable composition.
GVHD prophylaxis: The therapy patients receive single-agent tacrolimus. Conventional patients receive tacrolimus + methotrexate — a more immunosuppressive combination.
Infection risk at 1 year: Grade 3+ infections estimated at 44% (the therapy) vs 51% (conventional). Lower severe infection burden despite the single-agent prophylaxis.
Rehospitalization: 27.3% of therapy patients required rehospitalization vs 45.7% conventional. Total hospitalization days per patient: 30.6 vs 40.8.
Manufacturing: Single-cell precision sorting from matched donor blood. Orca reports a low single-digit failure rate across 500+ products manufactured.
What this means for the transplant landscape
The approval covers adults with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, and mixed-phenotype acute leukemia who have a matched donor and can tolerate myeloablative conditioning. That is a large addressable population. AML alone accounts for roughly 20,000 new cases annually in the US, and allogeneic transplant remains the only curative option for many.
The company's CEO Nate Fernhoff told Fierce Pharma it plans to launch at a handful of treatment centers and scale to approximately 25 by year-end. The developer tripled its Sacramento manufacturing team ahead of the approval and added East Coast capacity. The manufacturing failure rate — a critical concern for any cell therapy — has stayed at low single digits across more than 500 products produced for clinical trials.
Financially, the company raised over $600 million in private funding since its founding in 2016, with backing from venture capital firms. It now faces the question every biotech startup meets at approval: can commercial execution match clinical execution? The answer will depend on how quickly transplant centers adopt a new graft protocol and whether insurers cover the therapy without onerous prior authorization.
The company enters a stem cell transplant market that has seen limited innovation in graft composition for two decades. Existing alternatives — post-transplant cyclophosphamide for haploidentical transplants, anti-thymocyte globulin for T-cell depletion — reduce GVHD but come with their own toxicity profiles. The therapy is the first product to reformulate the graft itself with precision-sorted cells, creating a category that did not exist before approval.
What happens to the market a year from now?
Probability: 65% — initial uptake will concentrate at academic transplant centers already familiar with the Precision-T trial data. Wider community adoption depends on the company's ability to train centers on the three-bag infusion protocol and on payer coverage decisions expected in Q4 2026.
✅ Arguments for
Confirmation criteria: ≥500 patients treated commercially within 12 months; at least one major payer covering the therapy without step therapy by Q1 2027.
❌ Arguments against
Disconfirmation criteria: <12-month cGVHD-free survival curves converging toward control by month 24; <10 centers adopting the therapy within 6 months of launch.
Center onboarding rate — how many of the planned 25 centers are actively treating patients by December 2026.
Payer coverage decisions in Q4 2026 — Medicare and commercial payer policies for the therapy relative to standard HSCT.
Late-breaking durability data from the Precision-T extension study — cGVHD rates at 24 months.
Orca-Q Phase 1/2 data in haploidentical transplant — expands the addressable market beyond matched donors.
Development scenarios
🟢 Optimistic scenario (25%)
Implications: The company becomes the new standard of care for alloHSCT within 3 years, displacing unmanipulated grafts in matched-donor transplants.
🟡 Base-case scenario (55%)
Implications: The therapy becomes an important option for matched-donor transplant but does not fully replace conventional grafts. The company builds a sustainable commercial business while expanding into adjacent indications.
🔴 Pessimistic scenario (20%)
Implications: The company survives as a niche product for high-risk patients at elite academic centers, but fails to reach the commercial scale implied by the Phase 3 data.
